Drug Profile

N-desethyloxybutynin - Aytu BioPharma

Alternative Names: NRX 101 - NeuRx Pharmaceuticals; NT 0501; NT-502; NT0502

Latest Information Update: 27 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeuRx Pharmaceuticals
Developer Aytu BioPharma
Class Acetates; Amines; Cyclohexanes; Small molecules
Mechanism of Action Muscarinic receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Sialorrhoea

Most Recent Events

27 Jan 2022 No development reported - Phase-I for Sialorrhoea (In volunteers) in USA (PO) (Aytu Biopharma pipeline, January 2022)
22 Mar 2021 Neos Therapeutics has merged with Aytu BioScience to form Aytu BioPharma
09 Apr 2020 Neos Therapeutics has patent protection for N-desethyloxybutynin in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com